Positron emission tomography and brain monoamine neurotransmission -: Entries for study of drug interactions

被引:19
作者
Hartvig, P [1 ]
Bergström, M [1 ]
Antoni, G [1 ]
Långström, B [1 ]
机构
[1] Univ Uppsala, PET Ctr, Univ Hosp, S-75185 Uppsala, Sweden
关键词
positron emission tomography; neurotransmission; dopamine; serotonin;
D O I
10.2174/1381612023394458
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Monoamine neurotransmission is a complicated process with interactions between individual neurotransinitter pathways, multiple receptors with different responses and a variety of feedback loops regulating neurotransmitter synthesis, release, reuptake and effect on receptors. The system is further affected by a range of enzymes with co-factors controlling synthesis and degradation of monoamines. Positron emission tomography (PET) has evolved to a very versatile tool for the in vivo imaging and characterisation of physiology and biochemistry. The basis for its expansion during the last years has been a rapid development of labelling methods, allowing a range of tracer molecules to be generated and used in human and research animal Studies. The most important PET radionuclide is C-11 with a short half-life of approximately 20 minutes. This radionuclide is ideal for the labelling of organic molecules and for multitracer applications in research and drug development studies. PET has been used for a range of explorative studies on the monoamine neurotransmission, as exemplified by studies on the expression of dopamine and serotonin receptors as well as the rate of dopamine and serotonin synthesis. The present article gives examples of studies where PET has been used for the characterization of monoamine transmitter systems in experimental animals and in humans, both in healthy individuals and in patients with diseases affecting neurotransmission.
引用
收藏
页码:1417 / 1434
页数:18
相关论文
共 83 条
[1]  
Agren H, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p235A
[2]   The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT [J].
Antonini, A ;
Moresco, RM ;
Gobbo, C ;
De Notaris, R ;
Panzacchi, A ;
Barone, P ;
Calzetti, S ;
Negrotti, A ;
Pezzoli, G ;
Fazio, F .
NEUROLOGICAL SCIENCES, 2001, 22 (01) :47-48
[3]   Synthesis of some C-11-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain [J].
Bergstrom, M ;
Westerberg, G ;
Kihlberg, T ;
Langstrom, B .
NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (05) :381-388
[4]   MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: In vivo studies with positron emission tomography [J].
Bergstrom, M ;
Westerberg, G ;
Nemeth, G ;
Traut, M ;
Gross, G ;
Greger, G ;
MullerPeltzer, H ;
Safer, A ;
Eckernas, SA ;
Grahner, A ;
Langstrom, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (02) :121-128
[5]   C-11-harmine as a tracer for monoamine oxidase A (MAO-A): In vitro and in vivo studies [J].
Bergstrom, M ;
Westerberg, G ;
Langstrom, B .
NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (04) :287-293
[6]  
Bergstrom M, 1996, J NUCL MED, V37, P32
[7]  
BERGSTROM M, 1995, P EUR NEUR M AMST
[8]  
Cumming P, 1998, SYNAPSE, V29, P37, DOI 10.1002/(SICI)1098-2396(199805)29:1<37::AID-SYN4>3.0.CO
[9]  
2-C
[10]   QUANTIFICATION OF BENZODIAZEPINE RECEPTORS IN HUMAN BRAIN USING PET, [C-11] FLUMAZENIL, AND A SINGLE-EXPERIMENT PROTOCOL [J].
DELFORGE, J ;
PAPPATA, S ;
MILLET, P ;
SAMSON, Y ;
BENDRIEM, B ;
JOBERT, A ;
CROUZEL, C ;
SYROTA, A .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1995, 15 (02) :284-300